Tiziana Life Sciences Doses First Patient in Critical Phase 2 Alzheimer’s Trial
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).
On December 17, 2025, Tiziana Life Sciences announced that the first patient was dosed with intranasal foralumab in a Phase 2 trial for early Alzheimer’s disease. This trial explores foralumab as a monotherapy and in combination with FDA-approved therapies aiming to address residual neuroinflammation, a critical factor in Alzheimer’s progression. Supported by promising imaging data, this milestone may position Tiziana and foralumab as leaders in redefining disease modification strategies. Stakeholders may benefit from advancements in resolving neuroinflammation beyond current amyloid-clearing methods.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company specializing in breakthrough therapies through innovative drug delivery technologies. Their primary focus is on immunotherapy, with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as their lead development candidate. The company aims to improve the efficacy and safety of treatments and holds patents in alternative immunotherapy delivery methods.
Average Trading Volume: 352,210
Technical Sentiment Signal: Buy
Current Market Cap: $184.2M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.
